Statins are among the most widely prescribed drugs for the prevention of cardiovascular accidents. Well tolerated, has recently suggested an association with recent-onset diabetes. A trial has suggested that a 27% increase in the risk of diabetes with while rosuvastatin patients suggested an another taking Pravastatin has enjoyed a 30% lower risk.
There are little data on this subject, researchers at the Canada conducted a population-based study on 1.5 million resident in Ontario, to Canada to examine the relationship between the individual use of statin and recent-onset diabetes.
All patients were between the ages of 66 and more started statin therapy between 1997 and 2010. The median age was 73 years. Monitoring is completed at the end of 2010, or a maximum of five years following the beginning of statins, whichever came first. The primary outcome was incident diabetes.
Data were derived from the basis of the provision of drugs of Ontario, the Canadian Institute for Health Information Discharge Abstract Database and the Ontario Diabetes database. Statin drugs included in the study were: fluvastatin, lovastatin, Pravastatin, simvastatin, atorvastatin and rosuvastatin.
All studies used in patients treated with Pravastatin that turned out the comparison like this group have newly diagnosed positive effects diabetes in animal models and clinical trials.
471 250 patients were identified with no history of diabetes and who have been recently treated with a Statin. 54% were women. Atorvastatin represented more than half of all orders new Statin, followed by the rosuvastatin, simvastatin, Pravastatin, lovastatin, and fluvastatin.
The overall risk of developing diabetes was low, but this risk is increased in some patients taking statins. Between 162 and 407 patients should be treated with different Statins for a patient further develop diabetes. Patients treated with atorvastatin were found to have a 22% increase in the risk of new-onset diabetes, rosuvastatin a risk of increase of 18% and simvastatin a risk of increase of 10% compared with Pravastatin. In contrast, patients treated with fluvastatin ran a decreased risk of 5% and lovastatin, a risk of 1% decrease.
The rate of events was higher for atorvastatin (30 results per 1000 person-years) and rosuvastatin (34 per 1000 person-years). Simvastatin represents 26 results per 1000 person-years both fluvastatin and lovastatin to 21 results per 1000 person-years.
The researchers found consistent results in analyses of the use of Statins for primary prevention (when people without established disease are treated) and secondary prevention (when people with established diseases are treated). Their results also suggest that patients older at increased risk, regardless of the dose atorvastatin and simvastatin or know if therapy is used for primary or secondary prevention.
The researchers say that several factors may explain the increased risk of diabetes of recent onset in patients receiving some Statins including impaired insulin secretion and insulin release inhibited.
In conclusion, the researchers say clinicians should consider risk when considering the statin therapy. They add that "the preferential use of Pravastatin and potentially fluvastatin [] may be justified" and that Pravastatin may even be beneficial for patients at high risk for diabetes.
In an accompanying editorial, doctors from the University of Turku in Finland say "the overall profit of Statins than always clearly the possible risk of incident diabetes". They conclude that as Statins have been shown to reduce cardiovascular events in patients, they "play an important role in treatment".
Source-Eurekalert
No comments:
Post a Comment